Morepen Laboratories Ltd

AI
Morepen Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Morepen Laboratories Ltd

₹ 121 0.27%
28 Sep - close price
morepen.com BSE: 500288 NSE: MOREPENLAB
About

Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.[1]

Key Points

Business Segments[1] [2]
a) Active Pharmaceutical Ingredients (53% in FY26 vs 54% in FY25): [3]
The company has established leadership positions across key APIs, with a selective portfolio spanning anti-arthritis, cardiac care, anticoagulants, diabetes care, anti-allergy, CNS, anti-ulcerative, oncology, NASH/MASH, anti-platelet, and CKD treatment products. It has market-leading capacities of 140 MT Loratadine, 90 MT Montelukast, 300 MT Atorvastatin, 120 MT Fexofenadine, 36 MT Dapagliflozin, 60 MT Sitagliptin, 60 MT Rosuvastatin, 24 MT Empagliflozin, 150 MT Bempedoic Acid, and 24 MT Desloratadine, with several of these being among the world’s largest capacities. The company serves 500+ customers, generates 60%+ of its business from repeat customers, and exports to 90+ countries.

Website BSE NSE
  • Market Cap ₹ 6,611 Cr.
  • Current Price ₹ 121
  • High / Low ₹ 127 / 33.0
  • Stock P/E 56.3
  • Book Value ₹ 22.8
  • Dividend Yield 0.17 %
  • ROCE 8.05 %
  • ROE 5.33 %
  • Face Value ₹ 2.00
Edit ratios

Pros

Cons

  • Stock is trading at 5.31 times its book value
  • The company has delivered a poor sales growth of 8.73% over past five years.
  • Company has a low return on equity of 9.26% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
401 422 445 423 455 438 453 466 425 412 484 485 570
375 388 394 375 404 394 417 424 401 381 438 460 488
Operating Profit 26 34 51 48 52 44 36 42 24 31 46 24 83
OPM % 7% 8% 11% 11% 11% 10% 8% 9% 6% 7% 10% 5% 14%
2 3 4 4 3 5 5 5 4 30 4 8 5
Interest 0 0 2 1 1 1 1 5 4 4 4 4 5
Depreciation 8 8 8 10 6 2 5 16 9 11 10 6 8
Profit before tax 21 29 44 42 48 46 35 26 16 46 35 23 75
Tax % 29% 26% 27% 32% 25% 24% 24% 21% 26% 10% 22% 33% 24%
15 21 32 29 36 35 27 20 11 41 28 16 56
EPS in Rs 0.29 0.42 0.63 0.55 0.71 0.64 0.49 0.37 0.20 0.75 0.50 0.29 1.03
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
401 485 595 607 769 853 1,188 1,547 1,418 1,690 1,812 1,806 1,951
352 424 534 542 701 785 1,070 1,410 1,338 1,532 1,638 1,680 1,767
Operating Profit 48 62 61 65 68 69 119 137 80 159 174 126 184
OPM % 12% 13% 10% 11% 9% 8% 10% 9% 6% 9% 10% 7% 9%
1 -3 4 4 4 9 12 10 6 14 18 47 48
Interest 9 10 8 4 2 2 2 -7 2 4 8 16 17
Depreciation 39 35 34 34 40 37 30 28 28 33 29 36 36
Profit before tax 2 13 24 30 29 39 99 127 56 135 155 120 179
Tax % 6% -1% -0% -0% 1% 14% 1% 20% 31% 29% 24% 20%
2 13 24 30 29 34 97 102 39 97 118 96 141
EPS in Rs 0.05 0.28 0.53 0.66 0.64 0.75 2.16 2.13 0.76 1.88 2.15 1.73 2.57
Dividend Payout % -0% -0% -0% -0% -0% -0% -0% -0% -0% -0% 9% 12%
Compounded Sales Growth
10 Years: 14%
5 Years: 9%
3 Years: 8%
TTM: 9%
Compounded Profit Growth
10 Years: 14%
5 Years: -8%
3 Years: 18%
TTM: 27%
Stock Price CAGR
10 Years: 18%
5 Years: 16%
3 Years: 48%
1 Year: 147%
Return on Equity
10 Years: 12%
5 Years: 10%
3 Years: 9%
Last Year: 5%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 90 90 90 90 90 90 90 96 102 102 110 110
Reserves 78 91 106 136 163 194 335 483 651 745 1,047 1,137
201 187 169 134 132 133 17 19 25 29 105 208
121 156 173 226 230 246 416 473 332 417 517 482
Total Liabilities 489 524 538 586 615 663 858 1,070 1,110 1,293 1,778 1,936
322 297 272 264 236 216 225 252 267 307 489 513
CWIP -0 -0 -0 -0 -0 -0 2 14 17 24 28 22
Investments -0 -0 -0 0 0 1 1 -0 -0 1 85 124
167 227 266 321 379 446 631 804 827 960 1,176 1,277
Total Assets 489 524 538 586 615 663 858 1,070 1,110 1,293 1,778 1,936

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
51 50 41 63 17 11 51 -60 -91 73 32 33
-32 -27 -14 -27 -13 -12 -70 -32 -47 -83 -322 -126
-19 -27 -24 -38 -0 5 47 66 144 5 300 97
Net Cash Flow -0 -4 3 -1 4 4 28 -26 6 -5 10 4
Free Cash Flow 46 41 31 37 6 -6 10 -127 -137 -8 -182 -127
CFO/OP 105% 81% 66% 98% 26% 25% 44% -26% -94% 70% 40% 46%

Ratios

Consolidated / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 51 66 57 73 64 59 56 59 68 70 65 67
Inventory Days 55 51 65 76 69 91 82 96 87 85 94 88
Days Payable 126 140 125 173 124 113 98 90 87 101 114 103
Cash Conversion Cycle -20 -23 -3 -24 9 37 40 65 69 54 45 53
Working Capital Days -20 -10 -86 -62 -34 -8 17 55 98 94 107 118
ROCE % 3% 8% 9% 9% 8% 10% 23% 23% 8% 17% 15% 8%

Insights

In beta
Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
API Export Share of Revenue
%

Log in to view insights

Please log in to see hidden values.

Login
Number of Countries Exported To
count
API Installed Capacity
KL (Kilo Liters)
API Sales Volume
MT (Metric Tons)
Cumulative Glucometer Installed Base
millions
Drug Master Files (DMFs) Filed
count
Number of Medical Representatives
count
Test Strips Sold (Annual)
millions

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

32 Recently
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
38.22% 38.22% 38.22% 38.22% 35.66% 35.66% 35.66% 35.66% 35.66% 35.66% 35.66% 35.66%
1.29% 2.11% 1.85% 1.67% 2.08% 2.22% 1.94% 1.72% 1.62% 1.62% 1.59% 1.46%
2.27% 2.21% 2.15% 2.14% 1.69% 1.64% 1.67% 1.50% 1.49% 1.25% 1.25% 1.28%
0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
58.20% 57.46% 57.76% 57.96% 60.57% 60.46% 60.72% 61.09% 61.22% 61.46% 61.50% 61.59%
No. of Shareholders 3,04,0013,04,2893,36,0193,48,7664,30,9294,48,3614,68,8604,61,1804,61,8534,53,1374,47,2864,34,912

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls